soluble RAGE

Soluble RAGE is a **truncated, extracellular form** of the receptor for advanced glycation end products (RAGE), generated either via alternative splicing (endogenous secretory RAGE, esRAGE, also known as RAGE_v1) or by proteolytic cleavage of membrane-bound RAGE (cleaved RAGE, cRAGE)[1][3][7]. Soluble RAGE retains the ligand-binding extracellular domain but lacks the transmembrane and cytoplasmic domains, resulting in its secretion and circulation in the plasma[1][2][7][9]. Functionally, soluble RAGE acts as a **decoy receptor**: it binds RAGE ligands—such as advanced glycation end-products (AGEs), S100 proteins, amyloid-β, and HMGB1—in the bloodstream, thereby preventing their interaction with the membrane-bound RAGE and attenuating downstream pro-inflammatory signaling[1][2][3][7][8]. This mechanism underlies its potential as both a **therapeutic agent** and **biomarker** in various chronic inflammatory, cardiovascular, metabolic, and neurodegenerative diseases[1][3]. Soluble RAGE has shown protective, anti-inflammatory effects in preclinical models and is primarily being explored as an experimental therapeutic protein, not a commercialized drug[3][5][8][9]. sRAGE itself is not a proprietary development; attempts at pharmacological production or recombinant protein therapy are mostly in academic and experimental settings.

Other names

soluble receptor for advanced glycation end-productssoluble receptor for AGEsendogenous secretory RAGEcleaved RAGE